# MagnetisMM-9 (NCT05014412)

> A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05014412
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Multiple Myeloma
- Interventions: Elranatamab
- Enrollment: 86
- Primary outcome: Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=magnetismm-9-nct05014412